Myeloma Trial, Recruiting NCT07446777 Sponsor: University of Miami Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT07446777
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People of any sex or gender
  • People who are able to give informed consent to participate
  • People who can speak, read, and understand English or Spanish
  • People who have a confirmed diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) (Group 1), or people who have a newly confirmed diagnosis of Multiple Myeloma (MM) and are about to start treatment for it (Group 2)
  • People whose myeloma treatment is being delivered at Sylvester Comprehensive Cancer Center or the University of Miami Health System (including connected sites)
  • People whose treating cancer doctor has given written approval for them to participate
  • People with a general health and activity level that meets a certain threshold, as assessed by their doctor using a standard scale (confirm with trial site if uncertain)
  • People who have not been regularly fasting for 12 hours or more overnight for at least half of the past 3 months
  • People whose current diet does not consistently follow a Mediterranean-style eating pattern — specifically, people not already meeting at least two of these three habits most of the time: eating 3 or more servings of vegetables per day, eating 3 or more servings of beans or legumes per week, or eating 1 or more servings of nuts per day
  • People who have access to the internet via a smartphone, tablet, or computer
  • People who are willing to be randomly assigned to either a dietary and fasting programme or a waitlist group

Who may not be able to join:

  • People under 18 years of age
  • People who are unable to give informed consent
  • People who cannot read or understand English or Spanish
  • People for whom a doctor has determined that changes to their diet would not be safe
  • People with a history of a clinical eating disorder
  • People with a history of dementia or a major psychiatric condition
  • People who have had a stroke, heart attack, or heart failure within the past year
  • People who have an autoimmune disease and are currently receiving treatment for it at the time of screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tracy E Crane, PhD, RDN, University of Miami

Phone: (305) 243-9832

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 April 2026
Est. completion
30 April 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility: Percentage of Participants That Agree to Participate; Retention Rate Among Participants Assigned to the Intervention Arm; Satisfaction Rate Among Participants on Both Arms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov